Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study.

Background: Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best predict mortality in hospitalized patients receiving active systemic treatment. Our main goal was to develop a predictive model for 90-day mortality upon admission.

Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy.

Unlabelled: High prevalence of placental-derived complications, such as preeclampsia and intrauterine growth restriction, has been reported in women with breast cancer (BC) treated with chemotherapy during pregnancy (PBC-CHT).

Aim: To ascertain whether PBC-CHT is associated with an imbalance of angiogenic factors, surrogate markers for placental insufficiency, that could explain perinatal outcomes.

Methods: Prospective study between 2012 and 2016 in a single institution.

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients.

Objective: To define recommendations that permit safe management of  antineoplastic medication, minimise medication errors and improve the safety of  cancer patients undergoing treatment.

Method: By reviewing the literature and consulting the websites of various health organisations and agencies, an expert committee from the  Spanish Society of Hospital Pharmacy and the Spanish Society of Medical  Oncology defined a set of safe practices covering all stages of providing cancer  therapy to patients. The Spanish Society of Oncology Nursing revised and  endorsed the final list.